Turning Point Therapeutics (NASDAQ:TPTX) and Processa Pharmaceuticals (OTCMKTS:PCSA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability and valuation.
Risk and Volatility
Turning Point Therapeutics has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500. Comparatively, Processa Pharmaceuticals has a beta of -0.68, suggesting that its share price is 168% less volatile than the S&P 500.
This table compares Turning Point Therapeutics and Processa Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Turning Point Therapeutics||N/A||-27.88%||-27.00%|
Valuation & Earnings
This table compares Turning Point Therapeutics and Processa Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Turning Point Therapeutics||N/A||N/A||-$72.13 million||($2.99)||-28.99|
|Processa Pharmaceuticals||N/A||N/A||-$3.36 million||N/A||N/A|
Institutional & Insider Ownership
87.3% of Turning Point Therapeutics shares are held by institutional investors. 23.2% of Turning Point Therapeutics shares are held by insiders. Comparatively, 54.6% of Processa Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This is a breakdown of recent ratings and recommmendations for Turning Point Therapeutics and Processa Pharmaceuticals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Turning Point Therapeutics||0||0||6||0||3.00|
Turning Point Therapeutics currently has a consensus price target of $82.50, suggesting a potential downside of 4.83%. Given Turning Point Therapeutics’ higher possible upside, research analysts plainly believe Turning Point Therapeutics is more favorable than Processa Pharmaceuticals.
Turning Point Therapeutics beats Processa Pharmaceuticals on 6 of the 8 factors compared between the two stocks.
Turning Point Therapeutics Company Profile
Turning Point Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib (TPX-0005) is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+ or ALK+ advanced solid tumors. Its pipeline also includes multi-targeted drug candidates TPX-0046, a RET/SRC inhibitor; TPX-0022, a MET/CSF1R/SRC inhibitor; and a series of ALK inhibitors. The company was incorporated in 2013 and is headquartered in San Diego, California.
Processa Pharmaceuticals Company Profile
Processa Pharmaceuticals, Inc., a pharmaceutical company, engages in the clinical development of drug products for the unmet medical needs. Its lead product candidate is PCS-499, an oral tablet for the treatment of necrobiosis lipoidica and radiation-induced fibrosis in head and neck cancer patients. The company is based in Hanover, Maryland.
Receive News & Ratings for Turning Point Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turning Point Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.